STR1720, a potential sensitizer for radiotherapy and cytotoxicity effects of NVB-BEZ235 in metastatic breast cancer cells.

CONCLUSION: Our result shows that combination of NVP-BEZ235 and SRT1720 may effectively improve late stage breast cancer cells therapeutics approach. Activation of SIRT1 and STAT3 in resistance breast cancer cells improves the in-vitro therapeutic efficacy of CRT. PMID: 29653746 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29653746?dopt=Abstract

Source: Pathology, Research and Practice - April 5, 2018 Category: Pathology Authors: Fatehi D, Soltani A, Ghatrehsamani M Tags: Pathol Res Pract Source Type: research